About | Free Trial

Last Update


This profile was last updated on . .

Is this you? Claim your profile.

Wrong John Didsbury?

Dr. John Didsbury

Founder and Chief Executive Officer

T3D Therapeutics Inc

Direct Phone: (919) ***-****       

T3D Therapeutics Inc

68 T.W. Alexander Drive

Research Triangle Park, North Carolina 27709

United States

Company Description

T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company incorporated in 2013. The company is committed to developing disease remedial therapeutics for the treatment of Alzheimer's disease and other CNS disorders. T3D-959, its le... more

Find other employees at this company (2)

Background Information

Employment History



GlaxoSmithKline plc


DARA BioSciences , Inc.

President and Chief Executive Officer

Drug Discovery Center of Innovation

Chief Executive Officer

Nuada Pharmaceuticals Inc

Associate Director Biology

Macronex Inc.


Genentech , Inc.


The University of Connecticut

Bachelor of Arts
University of Connecticut


Medical Microbiology
University of Vermont Medical College

Medicinal Microbiology
The University of Vermont College of Medicine

Web References (155 Total References)

"This is a significant milestone for ...

www.newsobserver.com [cached]

"This is a significant milestone for the company," said John Didsbury, T3D's CEO, in a statement.

T3D received approval from the Food and Drug Administration's Division of Neurology Products.
In March, T3D received a $1.8 million federal grant to support the Phase 2 trial, which is expected to involve 36 patients.
T3D-959 has demonstrated encouraging results in experiments with lab rats that hold out the promise that it could slow or even halt the progress of Alzheimer's, Didsbury said in March.
Founded in 2013, T3D is a virtual company that relies on outsourcing. It currently has two full-time and one-part time employee. T3D-959 was licensed in 2013 from Raleigh's Dara BioSciences, where Didsbury previously was chief scientific officer.

"This is a significant milestone for ...

www.ncbiotech.org [cached]

"This is a significant milestone for our company," said CEO John Didsbury, a former GlaxoSmithKline executive who took his pharmaceutical company experience into the entrepreneurship realm by founding T3D in 2013.

Commenting on the award, T3D ...

www.prweb.com [cached]

Commenting on the award, T3D Therapeutics' CEO John Didsbury said, "The National Institute on Aging's support will enable us to test our novel approach to developing an Alzheimer's disease drug therapy that has the potential to slow, stop or reverse the progression of disease.

John Didsbury T3D Therapeutics, Inc.

John Didsbury is CEO of ...

www.heraldsun.com [cached]

John Didsbury is CEO of T3D Therapeutics, a startup company that is seeking money to carry a diabetes candidate into studies as a treatment for Alzheimer's disease.

A Research Triangle Park drug development startup company is looking to raise money to further studies of a drug candidate that was originally targeted as a treatment for diabetes as a treatment for Alzheimer's disease. T3D Therapeutics CEO Dr. John Didsbury said the start-up company licensed a diabetes drug candidate from Dara BioSciences, a Raleigh-based pharmaceutical company focused on cancer supportive care products and on developing cancer treatments.
Didsbury was formerly chief scientific officer at Dara. "It's been a personal mission of mine to identify and develop a breakthrough medicine for any disease, and this particular drug is the culmination of the search," Didsbury said of the drug candidate, which he said he believes could have multiple mechanisms for treating Alzheimer's. "It's a tough haul, but one that just requires perseverance and tenacity." Didsbury said there are "striking similarities" between diabetes and Alzheimer's. The company's drug candidate would work in multiple ways by regulating enzymes involved in Alzheimer's defects, he said. "It acts in a myriad of ways, and like I said, it regulates the levels of certain key enzymes that are involved in the pathophysiology of the disease," he said.
Through T3D Therapeutics, Didsbury is looking to raise money to try to carry the diabetes drug that his company licensed from Dara into Phase 2 trials.
Didsbury said the additional funding will allow the company to do some pre-clinical work, but they're still evaluating their financial strategy to figure out a way to pay for Phase 2 trials. He said company has applied for grants from the National Institutes of Health and other organizations.

he T3D Therapeutics ...

ir.darabio.com [cached]

he T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound. e believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."

DARA previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products.
John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease.Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues.Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated."
Didsbury continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959."
John Didsbury, Ph.D. T3D Therapeutics CEO 919-949-0517

Similar Profiles

Other People with this Name

Other people with the name Didsbury

Tom Didsbury
Ferguson Financial Ltd

David Didsbury
Iveco Trucks New Zealand Ltd.

John Didsbury
Birchall Blackburn LLP

Lisa Didsbury
Special Metals Inc

Reeds Didsbury
Reeds Rains Limited

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory